REVVITY INC
RVTYNYSETrading Snapshot
- Day Range
- $151.06 β $153.99
- 52-Week Range
- $81.22 β $152.26
- Volume
- $1.71B
- Avg Volume
- $1.72B
- Shares Outstanding
- 111.6M
- Next Earnings
- Nov 30, 2026
Fundamentals Snapshot
- Annual Revenue
- $2.86B
- Last Q Revenue
- $730M
- P/E Ratio
- 70.3
- P/S Ratio
- 5.7x
- EPS (TTM)
- $2.10
- Dividend Yield
- 0.19%
- Dilution (1yr)
- β6.9%
Why Investors Own RVTY
- βHigh-growth profile β revenue up +8.9% YoY with expanding US Equity exposure.
- βHealthy economics β 49% gross margin and 18% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
REVVITY INC
RVTYAbout REVVITY INC
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates
REVVITY INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift RVTY price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
REVVITY INC announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.